» Authors » Xiting Huang

Xiting Huang

Explore the profile of Xiting Huang including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 77
Citations 588
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Xu C, Huang X, Hu Q, Xue W, Zhou K, Li X, et al.
Biomed Pharmacother . 2024 Oct; 180:117550. PMID: 39418963
Pancreatic cancer, characterized by a dismal prognosis and limited treatment options, persists as a formidable challenge in oncology. Trophoblast cell surface antigen 2 (TROP2)-directed antibody-drug conjugates have achieved great success...
2.
Huang X, Wang Q, Nan Y, Zhang X, Xu K, Ju D, et al.
Biomedicines . 2024 Sep; 12(9). PMID: 39335665
Although immunotherapy has shown potential in cancer treatment, current immunotherapeutics for bladder cancer are limited by a low response rate. Therefore, it is necessary to investigate other suitable immunotherapeutic targets...
3.
Xue W, Xu C, Zhang K, Cui L, Huang X, Nan Y, et al.
Cell Death Discov . 2024 Sep; 10(1):393. PMID: 39227365
Claudin18.2 (CLDN18.2) is overexpressed in cancers of the digestive system, rendering it an ideal drug target for antibody-drug conjugates (ADCs). Despite many CLDN18.2-directed ADCs undergoing clinical trials, the inconclusive underlying...
4.
Chen M, Zhang Y, Xu H, Huang X
Behav Sci (Basel) . 2024 Jun; 14(6). PMID: 38920783
The present study aims to examine the process through which empowering leadership shapes employees' work engagement and in-role performance by facilitating job-crafting behaviors, specifically seeking resources, seeking challenges, and reducing...
5.
Jiang H, Huang X, Li H, Ren F, Li D, Liu Y, et al.
Int J Biol Macromol . 2024 May; 270(Pt 2):132350. PMID: 38750839
Wound biofilms represent an elusive conundrum in contemporary treatment and diagnostic options, accredited to their escalating antibiotic resistance and interference in chronic wound healing processes. Here, we developed mesoporous polydopamine...
6.
Wang Y, Nan Y, Ma C, Lu X, Wang Q, Huang X, et al.
Cell Death Dis . 2024 Apr; 15(4):293. PMID: 38664366
Research and development on Nectin-4 antibody-drug conjugates (ADC) have been greatly accelerated since the approval of enfortumab vedotin to treat uroepithelial cancer. During the course of this study, we identified...
7.
Jiang Z, Huang X, Wang Z, Liu Y, Huang L, Luo X
J Med Internet Res . 2024 Jan; 26:e47134. PMID: 38194260
Background: Embodied conversational agents (ECAs) are computer-generated animated humanlike characters that interact with users through verbal and nonverbal behavioral cues. They are increasingly used in a range of fields, including...
8.
Huang X, Xiang X, Liu Y, Wang Z, Jiang Z, Huang L
JMIR Serious Games . 2023 Dec; 11:e39019. PMID: 38133907
Background: Chronic disease self-management is a public health issue of worldwide concern, and gamification is an emerging strategy to improve patients' participation in chronic disease self-management. Some studies have summarized...
9.
Xu C, Zhu M, Wang Q, Cui J, Huang Y, Huang X, et al.
J Nanobiotechnology . 2023 Nov; 21(1):410. PMID: 37932752
Background: Pancreatic cancer is a highly aggressive malignancy with limited treatment options and a poor prognosis. Trophoblast cell surface antigen 2 (TROP2), a cell surface antigen overexpressed in the tumors...
10.
Liu J, Xu T, Pan D, Fan J, Fu Y, Huang X, et al.
Int Immunopharmacol . 2023 Sep; 124(Pt B):110951. PMID: 37722258
Collagen is abundant but exposed in tumor due to the abnormal tumor blood vessels, thus is considered as a tumor-specific target. The A3 domain of von Willebrand factor (vWF A3)...